

DAFTAR PUSTAKA

1. Baker TR, Piver MS. Etiology, biology, and epidemiology of ovarian cancer. In: *Seminars in Surgical Oncology*. Vol 10. Wiley Online Library; 1994:242-248.
2. Zhang Y, Tang H, Cai J, et al. Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. *Cancer Lett*. 2011;303(1):47-55.
3. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. In: *Seminars in Surgical Oncology*. Vol 19. Wiley Online Library; 2000:3-10.
4. Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. In: *Seminars in Oncology Nursing*. Vol 35. Elsevier; 2019:151-156.
5. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. *Lancet Oncol*. 2012;13(8):790-801.
6. Keng SL, Wahab SBA, Chiu LB, Yusuf A. Awareness of ovarian cancer risk factors among women in Malaysia: a preliminary study. *Asian Pacific J Cancer Prev*. 2015;16(2):537-540.
7. Mousavi A-S, Mazhari MM, Guilani MM, Ghaemmaghani F, Behtash N, Akhavan S. Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively? *World J Surg Oncol*. 2010;8(1):1-5.
8. Yurkovetsky Z, Skates S, Lomakin A, et al. Development of a multimarker assay for early detection of ovarian cancer. *J Clin Oncol*. 2010;28(13):2159.
9. The University of Texas MD Anderson Cancer Center. Epithelial Ovarian Cancer. Published online 2021.
10. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2009 (vintage 2009 populations). *Bethesda, MD Natl Cancer Inst*. Published online 2012:1975-2009.
11. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during

the platinum era: a meta-analysis. In: *Database of Abstracts of Reviews of Effects (DARE): Quality-Assessed Reviews [Internet]*. Centre for Reviews and Dissemination (UK); 2002.

12. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, Van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. *Gynecol Oncol*. 1998;71(3):431-436.
13. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. *Am J Obstet Gynecol*. 1994;170(4):974-980.
14. Chang S-J, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. *Gynecol Oncol*. 2013;130(3):493-498.
15. Berek JS, Novak E. *Berek & Novak's gynecology*: Lippincott Williams & Wilkins. Published online 2007:1138-1185.
16. Chéreau E, Ballester M, Rouzier R, Coutant C, Daraï E. Advanced ovarian cancer: criteria of resectability. *Bull Cancer*. 2009;96(12):1189-1197.
17. Modarres-Gilani M, Ghaemmaghami F, Ansariipoor S, Zaeri MSF. Can Preoperative CA-125 Predict Resectability of Tumor in Patients with Advanced Epithelial Ovarian Carcinoma? *Acta Med Iran*. Published online 2004:419-423.
18. Andriono. *Sinopsis Kanker Ginekologi*. 3th ed. Pustaka Spirit; 2009.
19. Feng L, Liao S, Li L. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study. *J Ovarian Res*. 2020;13(1):1-8.
20. He C, Thapa N, Wang Y, et al. Prognostic significance of log (CA125)/PCI for the resectability of epithelial ovarian cancer: a retrospective study. *Cancer Manag Res*. 2020;12:2223.
21. May T, Stewart JM, Bernardini MQ, et al. The prognostic value of perioperative, pre-systemic therapy CA 125 levels in patients with high-grade serous ovarian

- cancer. *Int J Gynecol Obstet*. 2018;140(2):247-252.
22. May T, Oza AM. Measurement Tool of Chemotherapy Sensitivity in Advanced Ovarian Cancer. *Clin Cancer Res*. 2020;26(17):4432-4434.
 23. Deng H, Chen M, Guo X, et al. Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients. *Mol Genet genomic Med*. 2019;7(6):e672.
 24. Gubbels JAA, Felder M, Horibata S, et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. *Mol Cancer*. 2010;9(1):1-14.
 25. Konar H. *DC Dutta's Textbook of Gynecology*. JP Medical Ltd; 2016.
 26. Schultz KAP, Harris AK, Schneider DT, et al. Ovarian sex cord-stromal tumors. *J Oncol Pract*. 2016;12(10):940-946.
 27. George SHL, Garcia R, Slomovitz BM. Ovarian cancer: the fallopian tube as the site of origin and opportunities for prevention. *Front Oncol*. 2016;6:108.
 28. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin*. 2012;62(1):10-29.
 29. Fadillah A, Friadi A. Tumor Ganas Ovarium Residif Metastasis Karsinoma Musin ke Umbilikus, Peritoneum, dan Cairan Asites tanpa Ditemukan Tanda Keganasan pada Pemeriksaan Histopatologis Pasca Operatif Sebelumnya.
 30. De Jong W. Tumor Ovarium dalam Buku Ajar Ilmu Bedah. Published online 2014.
 31. Doufekas K, Olaitan A. Clinical epidemiology of epithelial ovarian cancer in the UK. *Int J Womens Health*. 2014;6:537.
 32. International Agency for Research on Cancer W. Cervical cancer estimated incidence, mortality and prevalence worldwide in 2012. *World Heal Organ*. Published online 2012.
 33. I. B. Rumbawa Pamaron. "Perbedaan Kadar Cancer Antigen-125 dan Human Epididimis_4 Pada Kanker Ovarium Tipe Epitelial Stadium I, Stadium II dan Stadium III". *Progr Pendidik Dr Spes I FK UNUD / RSUP Sanglah Denpasar*. Published online 2016.

34. Fachlevy AF, Abdullah Z, Russeng SS. Faktor risiko kanker ovarium di RSUP Wahidin Sudirohusodo Makassar. *Retrieved from <https://studylibid.com/doc/5873>*. 2012;95.
35. Sarwono Prawirohardjo. *Buku Acuan Nasional Pelayanan Kesehatan Maternal Dan Neonatal*. PT Bina Pustaka Sarwono Prawirohardjo; 2010.
36. Sung HK, Ma SH, Choi J-Y, et al. The effect of breastfeeding duration and parity on the risk of epithelial ovarian cancer: a systematic review and meta-analysis. *J Prev Med public Heal*. 2016;49(6):349.
37. Tsilidis KK, Allen NE, Key TJ, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. *Br J Cancer*. 2011;105(9):1436-1442.
38. Widodo J, Muhartono M, Wijaya SM, Rudiyanto W. Hubungan Faktor Risiko (Riwayat Keluarga, Obesitas, dan Alat Kontrasepsi Terhadap Derajat Histopatologi Kanker Ovarium di RSUD Dr. H. Abdul Moeloek Bandar Lampung Tahun 2018. *J Medula*. 2019;8(2):154-160.
39. Dewi M. Sebaran kanker di Indonesia, riset kesehatan dasar 2007. *Indones J Cancer*. 2017;11(1):1-8.
40. Qian F, Rookus MA, Leslie G, et al. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *Br J Cancer*. 2019;121(2):180-192. doi:10.1038/s41416-019-0492-8
41. Widodo J, Musyabiq Wijaya S, Waluyo Rudiyanto dan, Faktor Risiko Riwayat Keluarga H, Alat Kontrasepsi Terhadap Derajat Histopatologi Kanker Ovarium di RSUD Abdul Moeloek Bandar Lampung Tahun dan H, Rudiyanto W. Hubungan Faktor Risiko (Riwayat Keluarga, Obesitas, dan Alat Kontrasepsi Terhadap Derajat Histopatologi Kanker Ovarium di RSUD Dr. H. Abdul Moeloek Bandar Lampung Tahun 2018. *Medula*. 2019;8(2):154-160.
42. Sun Y, Zhou L, Shan T, et al. Variability of body mass index and risks of prostate, lung, colon, and ovarian cancers. *Front public Heal*. 2022;10.
43. Arthur RS, Dannenberg AJ, Kim M, Rohan TE. The association of body fat

composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank. *Br J Cancer*. 2021;124(9):1592-1605.

44. Bandera E V, Lee VS, Qin B, Rodriguez-Rodriguez L, Powell CB, Kushi LH. Impact of body mass index on ovarian cancer survival varies by stage. *Br J Cancer*. 2017;117(2):282-289.
45. Zhang M, Xie X, Lee AH, Binns CW, Holman CDJ. Body mass index in relation to ovarian cancer survival. *Cancer Epidemiol Biomarkers Prev*. 2005;14(5):1307-1310.
46. Dixon SC, Nagle CM, Thrift AP, et al. Adult body mass index and risk of ovarian cancer by subtype: A Mendelian randomization study. *Int J Epidemiol*. 2016;45(3):884-895. doi:10.1093/ije/dyw158
47. Leitzmann MF, Koebnick C, Danforth KN, et al. Body mass index and risk of ovarian cancer. *Cancer Interdiscip Int J Am Cancer Soc*. 2009;115(4):812-822.
48. Diergaarde B, Kurta ML. Use of fertility drugs and risk of ovarian cancer. *Curr Opin Obstet Gynecol*. 2014;26(3):125.
49. Andi Faizal Fachlevy, Zulkifly Abdullah and SSR. "Ovarian Cancer Risk Factors On Wahidin Sudirohusodo Hospital Makassar". *Fak Kesehat Masy Univ Hasanuddin*. Published online 2016.
50. DiSaia PJ, Creasman WT. Clinical gynecologic oncology [Internet]. Published online 2012.
51. Jordan SJ, Wilson LF, Nagle CM, et al. Cancers in Australia in 2010 attributable to and prevented by the use of combined oral contraceptives. *Aust N Z J Public Health*. 2015;39(5):441-445.
52. Lundberg FE, Johansson AL V, Rodriguez-Wallberg K, Gemzell-Danielsson K, Iliadou AN. Assisted reproductive technology and risk of ovarian cancer and borderline tumors in parous women: a population-based cohort study. *Eur J Epidemiol*. 2019;34(11):1093-1101.
53. Thomakos N, Diakosavvas M, Machairiotis N, Fasoulakis Z, Zarogoulidis P, Rodolakis A. Rare distant metastatic disease of ovarian and peritoneal

- carcinomatosis: a review of the literature. *Cancers (Basel)*. 2019;11(8):1044.
54. Knottenbelt DC, Snalune K, Kane JP. *Clinical Equine Oncology E-Book*. Elsevier Health Sciences; 2015.
55. Chesnais M, Lecuru F, Mimouni M, Ngo C, Fauconnier A, Huchon C. A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer. *PLoS One*. 2017;12(11):e0187245.
56. Rumack CM, Levine D. *Diagnostic Ultrasound E-Book*. Elsevier Health Sciences; 2017.
57. Li J, Dowdy S, Tipton T, et al. HE4 as a biomarker for ovarian and endometrial cancer management. *Expert Rev Mol Diagn*. 2009;9(6):555-566.
58. Schummer M, Drescher C, Forrest R, et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. *Gynecol Oncol*. 2012;125(1):65-69.
59. Sperber M. Environmental lung disorders induced by organic (nonmineral) agents. In: *Radiologic Diagnosis of Chest Disease*. Springer; 2001:401-408.
60. Yaznil MR, TJOKROPRAWIRO BA, Fauziah D. Hubungan Peritoneal Carcinomatosis Index dan Predictive Index Value Fagotti dengan Kadar Serum Fatty Acid Binding Protein 4 pada Kanker Ovarium Epitel Stadium Lanjut. *Indones J Cancer*. 2017;11(3):97-104.
61. Gu B, Xia L, Ge H, Liu S. Preoperative PET/CT score can predict complete resection in advanced epithelial ovarian cancer: a prospective study. *Quant Imaging Med Surg*. 2020;10(3):743.
62. Stromberg H. *DeWit's Medical-Surgical Nursing E-Book: Concepts & Practice*. Elsevier Health Sciences; 2020.
63. RICHARD W, BRANT W, WILIAM E, MAJOR NM. *Fundamental Of Body CT*. ELSEVIER INDIA; 2014.
64. Vosper M, Graham D, Cloke P. *Principles and Applications of Radiological Physics E-Book*. Elsevier Health Sciences; 2011.
65. Verri D. Pre-operative evaluation in advanced ovarian cancer: is ultrasound

- ready to replace computed tomography? *Int J Gynecol Cancer*. 2019;29(2):225-226.
66. Javadi S, Ganeshan DM, Qayyum A, Iyer RB, Bhosale P. Ovarian cancer, the revised FIGO staging system, and the role of imaging. *Am J Roentgenol*. 2016;206(6):1351-1360.
 67. Wulandari D. Perbandingan Antara Hasil Ultrasonografi Pre Operasi dengan Hasil Patologi Post Operasi Kista Endometriosis. Published online 2018.
 68. Salvo G, Odetto D, Pareja R, Frumovitz M, Ramirez PT. Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: a review of gaps and questions that remain. *Int J Gynecol Cancer*. 2020;30(6).
 69. Zanetta G, Rota S, Lissoni A, Meni A, Brancatelli GT, Buda A. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. *Gynecol Oncol*. 2001;81(1):63-66.
 70. Morales-Vásquez F, Pedernera E, Reynaga-Obregón J, et al. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma. *J Ovarian Res*. 2016;9(1):1-6.
 71. Moore RG, Miller MC, Eklund EE, Lu KH, Bast Jr RC, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. *Am J Obstet Gynecol*. 2012;206(4):349-e1.
 72. Rancourt C, Matte I, Lane D, Piché A. The role of MUC16 mucin (CA125) in the pathogenesis of ovarian cancer. *Ovarian cancer basic Sci Perspect Vol*. 2012;1:67-84.
 73. Kurniadi A, Hidayat YM, Suardi D, Susanto H, Gatot NAW, Prayitno H. Peran Serum IL-6 dan CA-125 Prabedah sebagai Prediktor Resektabilitas Tumor pada Kanker Ovarium Tipe Epitel. *Indones J Cancer*. 2018;11(4):151-158.
 74. Bachmann R, Brucker S, Stäbler A, et al. Prognostic relevance of high pretreatment CA125 levels in primary serous ovarian cancer. *Mol Clin Oncol*. 2021;14(1).

75. Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and Ovarian Cancer: A Comprehensive Review. *Cancers (Basel)*. 2020;12(12):3730.
76. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. *Rheumatol*. 2008;47(11):1635–1640. doi:10.1093/rheumatology/ken363
77. Argilés JM, López-Soriano FJ. The role of cytokines in cancer cachexia. *Med Res Rev*. 1999;19(3):223-248.
78. Macciò A, Madeddu C MG. Glucose metabolism. In: Mantovani G, editor. Cachexia and wasting: a modern approach. In: Springer; 2006:195-203.
79. Mani R, Jamil K, Vamsy MC. Specificity of serum tumor markers (CA125, CEA, AFP, Beta HCG) in ovarian malignancies. *Trends Med Res*. 2007;2(3):128-134.
80. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. *J Oncol*. 2010;2010.
81. Barakat RR, Markman M, Randall M. *Principles and Practice of Gynecologic Oncology*. Lippincott Williams & Wilkins; 2009.
82. Høgdall EVS, Christensen L, Kjaer SK, et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients: From The Danish “MALOVA” ovarian cancer study. *Gynecol Oncol*. 2007;104(3):508-515.
83. Nakagawa N, Koda H, Nitta N, et al. Reactivity of CA19-9 and CA125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis. *Acta Med Okayama*. 2015;69(4):227-235.
84. Levine, Douglas A; Santos, Jennifer De Los; Fleming, Gini; Barakat, Richard R; Markman MRM. *Handbook for Principles and Pretice of Gynecologic Oncology*.; 2009.
85. Adela CA. Karakteristik Karsinoma Ovarium Epitel di Rsup Haji Adam Malik Tahun 2013-2016. Published online 2017.

86. Koirala P, Moon AS, Chuang L. Clinical Utility of Preoperative Assessment in Ovarian Cancer Cytoreduction. *Diagnostics*. 2020;10(8):568.
87. Sibuea M, Lutfi M, Hakimi M. PERBANDINGAN COMPLETE RESPONSE PENDERITA KANKER OVARIUM STADIUM LANJUT YANG MENDAPAT REJIMEN PACLITAXEL-CARBOPLATIN DENGAN REJIMEN CYCLOPHOSPHAMIDE-ADRIAMYCIN-CISPLATIN SEBAGAI KEMOTERAPI LINI PERTAMA. *J Kesehat Reproduksi*. 2(2).
88. Roberts WS. Cytoreductive surgery in ovarian cancer: why, when, and how? *Cancer Control*. 1996;3(2):130-136.
89. Chang S-J, Bristow RE, Chi DS, Cliby WA. Role of aggressive surgical cytoreduction in advanced ovarian cancer. *J Gynecol Oncol*. 2015;26(4):336-342.
90. Department of Health. *The Annual Report of the Chief Medical Officer, 2014.*; 2015. <https://www.networks.nhs.uk/nhs-networks/staffordshire-shropshire-and-black-country-newborn/documents/documents/chief-medical-officers-report-2014>
91. Leitao Jr MM. Management of epithelial ovarian cancer. *Clin Adv Hematol Oncol H&O*. 2018;16(10):656-659.
92. Fotopoulou C, Hall M, Cruickshank D, et al. British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. *Eur J Obstet Gynecol Reprod Biol*. 2017;213:123-139.
93. Gerestein CG, Eijkemans MJ, Bakker J, et al. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer. *Anticancer Res*. 2011;31(11):4043-4049.
94. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. *Nat Rev Dis Prim*. 2016;2(1):1-22.
95. Berek JS HN. *Berek & Hacker ' s Gynecologic Oncology Seventh Edition*. Wolters Kluwer Health; 2021.
96. Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative

serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. *Gynecol Oncol.* 2000;77(2):227-231.

97. Lertkhachonsuk A, Buranawongtrakoon S, Lekskul N, Rermluk N, Wee-Stekly W, Charakorn C. Serum CA19-9, CA-125 and CEA as tumor markers for mucinous ovarian tumors. *J Obstet Gynaecol Res.* 2020;46(11):2287-2291.
98. Pradjatmo H, Siswishanto R, Prawitasari S. Hubungan Kadar CA-125 Praoperatif terhadap Prognosis Survival Penderita Kanker Ovarium Epitelial di RSUP Dr. Sardjito. *J Kesehat Reproduksi.* 2014;5(1):15-23.
99. Ushan EP, BUDIONO B. Perbandingan Uji Diagnostik Mesothelin Serum dengan CA-125 pada Kanker Ovarium Tipe Epitel. *Indones J Cancer.* 2015;9(2):71-81.
100. Winarno GNA, Hidayat YM, Soetopo S, Krisnadi SR, Tobing MDL, Rauf S. The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers. *BMC Res Notes.* 2020;13(1):1-7.
101. Obeidat B, Latimer J, Crawford R. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. *Gynecol Obstet Invest.* 2004;57(3):153-156.



